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Abstract 
Background: Type 2 diabetes complications cause a serious emotional and economical burden to patients and 
healthcare systems globally. Management of both acute and chronic complications of diabetes, which dramatically 
impair the quality of patients’ life, is still an unsolved issue in diabetes care, suggesting a need for early identification of 
individuals with high risk for developing diabetes complications.
Methods: We performed a genome-wide association study in 601 type 2 diabetes patients after stratifying them 
according to the presence or absence of four types of diabetes complications: diabetic neuropathy, diabetic nephrop-
athy, macrovascular complications, and ophthalmic complications.
Results: The analysis revealed ten novel associations showing genome-wide significance, including rs1132787 
(GYPA, OR = 2.71; 95% CI = 2.02–3.64) and diabetic neuropathy, rs2477088 (PDE4DIP, OR = 2.50; 95% CI = 1.87–3.34), 
rs4852954 (NAT8, OR = 2.27; 95% CI = 2.71–3.01), rs6032 (F5, OR = 2.12; 95% CI = 1.63–2.77), rs6935464 (RPS6KA2, 
OR = 2.25; 95% CI = 6.69–3.01) and macrovascular complications, rs3095447 (CCDC146, OR = 2.18; 95% CI = 1.66–2.87) 
and ophthalmic complications. By applying the targeted approach of previously reported susceptibility loci we man-
aged to replicate three associations: MAPK14 (rs3761980, rs80028505) and diabetic neuropathy, APOL1 (rs136161) and 
diabetic nephropathy.
Conclusions: Together these results provide further evidence for the implication of genetic factors in the develop-
ment of type 2 diabetes complications and highlight several potential key loci, able to modify the risk of developing 
these conditions. Moreover, the candidate variant approach proves a strong and consistent effect for multiple variants 
across different populations.
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Background
The past few decades have shown a marked increase in 
the number of patients with diabetes rising from 151 
million (4.6% of the global population) in 2000 to 463 
million (9.3%) in 2019 [1]. The risk of type 2 diabetes 
(T2DM), the most common type of diabetes, is modi-
fied by a strong interaction between environmental and 
genetic factors [2, 3]. T2DM is a multifactorial disease 
with a population-specific heritability (26% in the Euro-
pean population) [4]. A number of common variants 
implicated in the pathogenesis and genetic architecture 
of T2DM have been identified so far, some of them also 
capable of modifying the pharmacologic response to 
antidiabetic drugs [5, 6].
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Uncontrolled T2DM can lead to long-term illnesses 
or chronic health conditions divided into microvascular 
complications, such as diabetic retinopathy, nephropathy, 
neuropathy, and macrovascular complications, includ-
ing stroke, heart disease, and peripheral vascular disease 
[7], accounting for 53% of direct health costs of diabetes 
with cardiovascular and renal complications contribut-
ing to the greatest financial burden [8, 9]. Moreover, dia-
betic patients show increased all-cause mortality rates, 
especially cardiovascular deaths (HR 2.6, 95% CI 1.4–4.7) 
[10].
Studies show evidence of considerable genetic compo-
nent predisposing to diabetic complications, explaining 
even around 50% of the risk of proliferative retinopathy 
[11]. In the last few decades, genetic research including 
genome-wide association studies (GWAS), linkage analy-
sis, and candidate gene approach has revealed several 
susceptibility loci for diabetic retinopathy and nephropa-
thy (VEGF, CAT , FTO, UCP1, and INSR), and also mac-
rovascular complications (ADIPOQ). Nevertheless, they 
explain only a small proportion of the phenotypic vari-
ation observed in T2DM patients [12–17], justifying a 
need for identification of novel genetic risk factors for 
T2DM complications and improvement of knowledge 
about molecular mechanisms underlying these comorbid 
conditions.
Since the high impact of population specificity for the 
discrimination of genetic variants and their contribution 
to the phenotype of interest is evidenced by a number 
of SNPs that failed to replicate in different populations, 
both discovery and replication studies in populations of 
different ancestries are needed [18, 19]. An example of 
population-specific allele frequency is rs61736969, the 
risk variant of T2DM, which is located in the TBC1D4 
(TBC1 Domain Family Member 4) gene. It is highly fre-
quent (minor allele frequency of 17%) in the Greenlan-
dic population, nevertheless, it has not been present so 
far in European individuals, most probably due to differ-
ent linkage disequilibrium patterns [20]. Although poor 
glycemic control is considered to be the driving factor of 
T2DM complications, early genotype-based identifica-
tion of individuals at high risk of diabetic complications 
may promote the prevention or, at least, delay of the dis-
ease [21]. In this study, we aimed to discriminate novel 
susceptibility loci for T2DM complications and replicate 
the findings of other GWAS in the study cohort from 
the Genome Database of the Latvian Population (LGDB) 
[22].
Methods
Study group and phenotype definitions
In total, the study cohort consisted of 601 T2DM patients 
of European ancestry with and without a medical history 
of diabetes complications, selected from the participants 
of LGDB (recruited from June 2007 to November 2016) 
according to the following inclusion criteria: (1) clinically 
confirmed diagnosis of T2DM (E11 diagnosis code, ICD-
10), (2) information on age at diagnosis, sex, weight, and 
height available, (3) records of national diabetes registry 
and Latvian hospital inpatient discharges available. Writ-
ten broad consent was obtained from every subject dur-
ing the recruitment in LGDB.
The collection of blood samples and relevant anthro-
pometric data was ensured by LGDB according to their 
standard procedures [22]. Associated clinical data, 
including the diagnosis date of T2DM, date and type of 
diabetes complications, HbA1c measures, and medica-
tions used, were obtained from the records of Diabetes 
registry, Latvian hospital inpatient discharges, outpatient 
progress notes, and pharmacy recipe records, provided 
by The Centre for Disease Prevention and Control of Lat-
via and National Health Service of Latvia (Approval No. 
3, Decision No. 7.1–3/3). The data about diabetic com-
plications present for T2DM patients involved in LGDB 
were applied for accurate stratification of 601 T2DM 
patients in four phenotype-based groups according to the 
type of complications experienced: diabetic neuropathy, 
diabetic nephropathy, ophthalmic complications, and 
macrovascular complications. The definition of pheno-
types and patient stratification in different complication 
groups was done as follows:
1. Diabetic neuropathies: clinical diagnosis codes (ICD-
10) E11.4 and E11.5, records of amputation of the 
leg/toe, gangrene, shunting and angioplasty, and 
presence of intermittent claudication or fresh ulcers 
since the diagnosis of T2DM.
2. Diabetic nephropathies: clinical diagnosis code E11.2 
or records of kidney failure, kidney transplantation, 
renal replacement therapy, microalbuminuria, hemo-
dialysis, peritoneal dialysis performed after the diag-
nosis of T2DM.
3. Ophthalmic complications: clinical diagnosis code 
E11.3 or records of photocoagulation, maculopathy, 
retinopathy, operative therapy, blindness made since 
the diagnosis of T2DM.
4. Macrovascular complications: clinical diagnosis 
codes I95, I20, I21, I24, I25, I50, I60, I61, I63, I64, and 
records of coronary shunting and angioplasty after 
the diagnosis of T2DM.
ICD-10-based phenotype definitions corresponding to 
the Latvian guidelines of diabetes management are gen-
erally used in clinical practice in Latvia. Subjects with 
the above-mentioned diagnosis codes or medical events 
recorded were considered as cases in their corresponding 
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complication groups, while T2DM patients with no 
evidence of complications of interest during their fol-
low-up period were recognized as controls in the par-
ticular group. Subjects experiencing specific diabetes 
complications before the set of T2DM diagnosis were 
excluded from the analysis of a particular complication 
group, explaining the variable total number of individu-
als among all complication groups tested. The follow-up 
period which coincides with diabetes duration was con-
sidered as time since the set of T2DM diagnosis until the 
date of diabetes complication recorded for cases or the 
date of the last entry in the National registry for control 
subjects. Administration of medications was considered 
in a group-specific manner, accounting for angiotensin 
II receptor blockers and angiotensin-converting enzyme 
inhibitors in the analysis of all complication groups ana-
lyzed and additional lipid-modifying agents in the analy-
sis of macrovascular complications. In order to adjust 
for the inter-individual variability of glycaemic control, 
a key factor in the development of T2DM complications, 
the median HbA1c level during the observation period 
was fitted as a covariate, irrespective of the antidiabetic 
therapy used. Sex, age at the diagnosis of T2DM, body 
mass index (BMI), diabetes duration, and use of particu-
lar medications were also included among the covariates.
DNA extraction and genotyping
Within the framework of this study DNA samples from 
601 T2DM patients were used. DNA was isolated from 
peripheral blood leukocytes using a phenol–chloroform 
extraction method according to LGDB standard proce-
dures [22]. DNA samples were genotyped with the Infin-
ium Global Screening Array (Illumina, USA) on the iScan 
System microarray scanner (Illumina, USA). Illumina 
Genome Studio v2.0 was used to convert raw data into 
PLINK format and workflow described in Marees et  al. 
[23]. used for data quality control. SHAPEIT v2.r900 [24] 
and IMPUTE2 [25] were used for genotype phasing and 
genotype imputing. Imputed data were filtered using the 
following parameters: marker correlation (INFO) > 0.8, 
hard call threshold 0.1, minor allele frequency > 1%, 
Missingness < 2%.
Statistical analysis
Association analyses corresponding to four different 
complication groups (macrovascular complications, 
diabetic neuropathy, diabetic nephropathy, ophthalmic 
complications) were performed using PLINK v1.9 logis-
tic regression with covariates: median HbA1c, sex, age at 
the diagnosis, diabetes duration, BMI, medications used. 
A genome-wide significance threshold of P < 5 × 10−8 was 
defined.
For the targeted analysis candidate variants were 
selected from GWAS Central [26] (http://www.gwasc 
entra l.org/) and GWAS Catalog [27] (https ://www.ebi.
ac.uk/gwas/home), based on previously reported asso-
ciation with T2DM complications: diabetic neuropathy 
(4 allelic variants selected), macrovascular complications 
(43 allelic variants selected), ophthalmic complications 
(98 allelic variants selected) and diabetic nephropathy 
(49 allelic variants selected). A complete list of selected 
SNPs, their positions, and associated traits is provided 
in Additional file 1. False discovery rate (FDR) according 
to the Benjamini–Hochberg procedure was calculated to 
account for multiple testing and the threshold was set at 
0.05.
Manhattan plots and Q-Q plots were generated in R 
v3.5.3 using the qqman package, while the Venn diagram 
was developed in the online visualization tool Venny 
2.1.0. Statistical analysis of anthropometric measures and 
biochemical data was performed in R v3.5.3. by applying 
the Wilcoxon rank-sum test and Pearson’s chi-squared 
test with a p-value threshold < 0.05. For identification of 
the functional role of allelic variants expression quantita-
tive trait locus (eQTL) analysis was conducted by using 
the open-access Genotype Tissue Expression (GTEx) 
database [28]. The tissue types for eQTL analysis were 
carefully selected considering the etiology of the dis-
eases (artery, nerve, heart, skin, blood) [29]. The p-value 
threshold of 0.05 was used to discriminate significant 
associations. Variant Effect Predictor and Linkage Dis-
equilibrium (LD) data from 1000 Genome project (Utah 
Residents (CEPH) with Northern and Western European 
Ancestry) were employed to explore the functional con-
sequences of each variant and other variants in LD [30]. 
To evaluate the potential SNP effects on quantitative 
phenotypes, analyses of variant association with HbA1C 
and BMI were performed using PLINK v1.9—assoc func-
tion for quantitative phenotypes, where the genome-wide 




We studied a cohort of 601 T2DM patients of which 241 
were men and 360 women aged 22 to 82 years (average 
age 56.86 ± 10.24 years) stratified as controls or cases in 
four complication groups tested (diabetic nephropathy 
n = 601, diabetic neuropathy n = 600, ophthalmic com-
plications n = 601 and macrovascular complications 
n = 559), based on corresponding diagnosis or medi-
cal events experienced after the onset of T2DM. A phe-
notype-based distribution of subjects among different 
complication groups is shown in Fig. 1. After inspection 
of patient anthropometric data, we observed that T2DM 
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patients experiencing ophthalmic complications and dia-
betic neuropathy were significantly younger compared to 
the group of patients without particular complications 
while those with diabetic nephropathy, macrovascular 
and ophthalmic complications were characterized by 
longer duration of diabetes. As expected, median gly-
cated hemoglobin levels were higher in cases (patients 
with specific complications) compared to controls 
(patients without the same diabetes complication) except 
for the diabetic nephropathy group (Table 1).
After quality control and filtering 5 378 539 SNPs were 
used for further testing in each T2DM complication 
group. The total genotyping rate was > 0.99 in all of the 
tested T2DM complication groups. The genomic infla-
tion factor was negligible in all data sets based on median 
chi-squared statistics: 1.02 for neuropathies, 1.02 for 
macrovascular complications, 1.01 for ophthalmic com-
plications, and 1.00 for nephropathies. After adjustments 
for age, sex, BMI, diabetes duration, median HbA1c, 
and medications used ten susceptibility loci were iden-
tified for different T2DM complications (Fig.  2), among 
them rs1132787 (GYPA) and rs522521 (LOC105371557) 
showed an association with diabetic neuropathy, 
rs2477088 (PDE4DIP), rs522521 (LOC105371557), 
rs4852954 (NAT8), rs6032 (F5), rs6935464 (RPS6KA2), 
rs7236163 (ZNF519), rs3095447 (CCDC146) were sig-
nificantly associated with macrovascular complications, 
and only variant rs3095447 (CCDC146) was related to a 
greater risk of ophthalmic complications, while no signif-
icant hits were found for diabetic nephropathy (Table 2, 
Additional file 2).
The functional consequences of the identified variants 
were evaluated by the eQTL analysis, which was con-
ducted in GTEx database by focusing only on those tissue 
types that may be relevant or even damaged accord-
ing to the etiology of the disease [29]. Three out of eight 
novel allelic variants identified in this study appeared to 
be significantly associated with the expression of multi-
ple nearby genes: rs4852954 (ALMS1, DUSP11, NAT8, 
ALMS1P1, TPRKB, ALMS1-IT1, RP11-434P11.2), 
rs7236163 (ZNF519, RP11-411B10.2), and rs3095447 
(RP11-467H10.1, FGL2, PMS2P9, GSAP, SPDYE18, 
FAM185BP, CCDC146, UPK3BP1). See Additional file 3 
for the full list of the identified associations.
Targeted analysis
In order to investigate if previously reported associa-
tions in other populations are also true in our study 
Fig. 1 Venn diagram showing the distribution and overlap of cases among the analyzed T2DM complication groups
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cohorts, we performed a targeted analysis in the same 
subjects and stratification in complication groups (dia-
betic neuropathy, macrovascular complications, ophthal-
mic complications, and diabetic nephropathy) (Table  1) 
by performing an association analysis for 194 candi-
date variants in total. Information on previously known 
allele-trait associations reported in both GWAS Catalog 
and GWAS Central was used for the selection of risk 
variants associated with at least one group of the tested 
T2DM complications (see Additional file 1 for a full list 
of selected candidate SNPs). The genotyping rate in all of 
the complication groups analyzed was > 0.99. By applying 
the targeted approach we managed to replicate two sig-
nificant associations for diabetic neuropathy rs3761980 
and rs80028505, both mapping to MAPK14 loci and one 
significant hit (rs136161, APOL1) for diabetic nephropa-
thy (Table 3) in our study cohort.
Discussion
Here we present the results of the genome-wide asso-
ciation study for T2DM complications performed in 
a population of Latvia for the first time, revealing 10 
susceptibility loci for T2DM complications, including 
diabetic neuropathy, macrovascular and ophthalmic 
complications. As in other reports aimed to identify the 
risk factors of T2DM complications [15, 32], the control 
group of our study consisted of T2DM patients with no 
evidence of the complication type of interest instead of 
conventional healthy subjects, since the implementation 
of healthy controls would rather reveal genetic associa-
tions with the diagnosis of T2DM itself, not the T2DM 
complications.
We found two novel variants (rs1132787 and rs522521) 
associated with diabetic neuropathy and none of them 
have been linked to any disease or specific phenotype 
before. Variant rs1132787 is located within the 3′ UTR 
of a gene coding for glycophorin A coding (GYPA). 
Glycophorin A is the major erythrocyte membrane 
sialoglycoprotein. Although it has not been directly 
associated with susceptibility to any T2DM-related con-
dition before, studies report a significant upregulation 
of the GYPA gene in the dorsal root ganglia of a mouse 
model of T2DM and the metabolic syndrome, and even 
type 1 diabetes with diabetic polyneuropathy [33, 34]. 
Moreover, copy number variation overlapping GYPA 
has been already linked to body mass index, obesity, and 
obesity-related traits, such as weight, hip circumference, 
and waist circumference, providing more evidence for 
the potential contribution of GYPA in the development 
of diabetic complications [35]. Because of the multiple 
evidence of the implication of GYPA gene in neuropa-
thies and metabolic traits, and the potential functional 
consequence of the top variant rs1132787 located within 
the 3′UTR of the gene, we consider the GYPA gene as 
the first candidate for future functional validation stud-
ies. Nevertheless, credible evidence for this association 
should be established first by performing a replication 
study with larger sample size. The other identified risk 
variant rs522521 is located near the poorly characterized 
gene LOC105371557 with yet unknown function.
In total, seven variants reached genome-wide signifi-
cance for the association with macrovascular complica-
tions of T2DM. The strongest association was exhibited 
by an intron variant of the Phosphodiesterase 4D Inter-
acting Protein coding gene (PDE4DIP). Although the 
rs2477088 variant has not been previously linked to 
any T2DM manifestations, PDE4DIP, also known as 
myomegalin or cardiomyopathy-associated protein 2, 
is a well-known contributor of the microtubule control 
process [36] and some previous evidence exist indi-
cating on the potential role of the gene in macrovas-
cular diseases and T2DM. The exome sequencing has 
revealed a rare variant of PDE4DIP, which significantly 
increases the risk of ischemic stroke [37], moreover, 
CpG island methylation in leukocytes annotated to 
PDE4DIP contributes to the epigenetic fingerprint of 
myocardial infarction [38], and finally, the gene is also 
significantly downregulated in liver of T2DM patients 
[39]. Another risk allele (rs4852954) identified in the 
analysis of macrovascular complications is located near 
the N-Acetyltransferase 8 coding gene (NAT8) and has 
been previously associated with systolic blood pres-
sure and renal function in the Estonian population [40] 
which is genetically close to the Latvian population 
[41]. Although NAT8 gene has not been linked with 
T2DM macrovascular complications before, it is con-
sidered to be a susceptibility locus for diabetic kidney 
disease [42]. In addition, we found the coagulation fac-
tor 5 coding gene (F5) among the risk loci of macrovas-
cular complications. The variant rs6032 is located only 
around 7 kb from the Factor V Leiden (rs6025), which 
has been strongly associated with ischemic stroke and 
Fig. 2 Manhattan plots for GWAS of T2DM complications. a Diabetic neuropathies, b macrovascular complications, c ophthalmic complications. 
X-axis shows chromosomal positions. Y-axis shows –log10 P-values. The red lines indicate a genome-wide significant threshold of P < 5 × 10−8, and 
the blue lines denote a suggestive significance threshold of P < 5 × 10−5. Association signals that reached genome-wide significance are denoted 
by reference SNP ID number
(See figure on next page.)
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incident venous thrombosis before [43, 44], therefore 
we may speculate that in rs6032 carriers manifesta-
tion of the trait are amplified by the presence of T2DM. 
Although rs6032 is the only missense variant among 
the top hits, it is categorized as benign according to 
SIFT and PolyPhen. Nevertheless, the variant is in the 
LD with rs4524, the risk variant for venous thrombo-
embolism (OR = 1.14; CI = 1.11–1.16) [45].
Finally, 4 more loci showed genome-wide significance 
for the association with macrovascular complications, 
among them rs6935464, located within the RPS6KA2 
gene coding for Ribosomal Protein S6 Kinase A2, which 
is involved in cardiac myocyte stress responses and even 
considered as a therapeutic target for the prevention of 
heart failure [46], and rs3095447, an intron variant of 
Coiled-Coil Domain Containing 146 gene (CCDC146) 
which is also the only significant hit for ophthalmic com-
plications in our data. The last two variants (rs522521 
and rs7236163) identified in the analysis of macrovas-
cular complications are located in the intergenic regions 
near genes LOC105371557 and ZNF519 respectively, and 
both have not been linked to any disease before.
We noticed two of the variants (rs522521, rs3095447) 
appearing among the top hits of multiple complication 
groups, which seems rational since a number of patients 
had experienced more than one type of complication, 
resulting in a notable overlap of patients among four 
tested phenotype groups (Fig. 1). This finding may be also 
explained by similar etiologic characteristics between 
microvascular diabetic complications involving small 
vessels (neuropathy, nephropathy, ophthalmic complica-
tions) and macrovascular complications related to large 
vessel damage, with chronic hyperglycemia as the main 
cause of all these comorbidities. Moreover, microvascu-
lar and macrovascular complications tend to be strongly 
interconnected, and the damage of small vessels may con-
tribute to the manifestations of heart disease in diabetes 
[7], which coincides with our data showing only a small 
number of T2DM patients corresponding to one compli-
cation group only, while 18% (n = 109) of T2DM patients 
Table 2 Susceptibility loci associated with type 2 diabetes mellitus complications
CHR chromosome and base pair position in Human Genome build hg19, A1 minor allele, A2 major allele, OR odds ratio for the minor allele, CI confidence interval 95%, 
MAF minor allele frequency, MAF European minor allele frequency observed in the European population [31]
CHR Closest gene SNP A1/A2 OR (95% CI) P‑value MAF cases/controls MAF European
Diabetic neuropathy
4:145030546 GYPA rs1132787 T/C 2.71 (2.02–3.64) 3.23E−11 0.37/0.16 0.31
17:15733545 LOC105371557 rs522521 A/C 0.49 (0.38–0.64) 5.07E−08 0.37/0.56 0.70
Macrovascular complications
1:144936353 PDE4DIP rs2477088 T/C 2.50 (1.87–3.34) 6.11E−10 0.51/0.32 0.58
17:15733545 LOC105371557 rs522521 A/C 0.42 (17.32–0.56) 6.95E−10 0.40/0.60 0.70
2:73870010 NAT8 rs4852954 T/C 2.27 (2.71–3.01) 1.26E−08 0.50/0.31 0.61
1:169511555 F5 rs6032 T/C 2.12 (1.63–2.77) 2.62E−08 0.56/0.37 0.73
6:167114208 RPS6KA2 rs6935464 A/G 2.25 (6.69–3.01) 3.89E−08 0.44/0.26 0.57
18:14150724 ZNF519 rs7236163 T/C 2.14 (18.63–2.82) 4.97E−08 0.46/0.27 0.58
7:76764970 CCDC146 rs3095447 A/C 2.16 (7.64–2.84) 4.98E−08 0.55/0.37 0.79
Ophthalmic complications
7:76764970 CCDC146 rs3095447 A/C 2.18 (1.66–2.87) 2.55E−08 0.61/0.40 0.79
Table 3 Candidate variants showing a significant association with type 2 diabetes complications
CHR chromosome and base pair position in Human Genome build hg19, A1 minor allele, A2 major allele, OR odds ratio for the minor allele, CI confidence interval 95%, 
FDR false discovery rate by Benjamini & Hochberg method, MAF minor allele frequency, MAF European: minor allele frequency observed in the European population 
[31]
CHR Closest gene SNP A1/A2 MAF cases/
controls
MAF European OR (95% CI) P‑value FDR References
Neuropathies
6:35993906 MAPK14, SLC26A8 rs3761980 G/A 0.13/0.09 0.10 1.58 (1.08–2.33) 1.94E-02 3.88E-02 Meng et al. [49]
6:35998388 MAPK14 rs80028505 T/C 0.13/0.09 0.11 1.58 (1.08–2.33) 1.94E-02 3.88E-02 Meng et al. [49]
Nephropathies
22:36657432 APOL1 rs136161 G/C 0.47/ 0.29 0.40 2.00 (1.40–2.86) 1.41E-04 6.93E-03 Iyengar et al. [50]
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included in this study had experienced multiple manifes-
tations during the observation period, corresponding to 
all four analyzed complication types.
According to Ensembl Variant Effect Predictor, most 
of the identified variants are intronic, though rs1132787, 
which is located in the enhancer site, and rs4852954 lay-
ing within the promoter flanking region may disrupt the 
functions of regulatory elements and therefore modulate 
the gene expression patterns. Some of the genes affected 
by the identified eQTLs (Additional file 3) are previously 
associated with the performance of the vascular system, 
for instance, expression of Fibrinogen-like protein 2 cod-
ing gene (FGL2) in endothelial cells has been previously 
linked to microthrombosis and cardiac impairment in 
rats with T2DM [47], and Alstrom Syndrome Protein 1 
coding gene (ALMS1) is associated with Alström syn-
drome and characteristic dilated cardiomyopathy [48]. 
According to GTEx data, rs3095447 negatively corre-
lates with FGL2 expression in heart and artery, while 
rs4852954 is linked to lower ALMS1 levels in whole 
blood and skin tissue, suggesting the possible functional 
implication of these variants in the pathogenesis of the 
disease. In order to explore additional effects of the top 
hits, quantitative phenotype analyses were performed, 
revealing significant associations between rs6935464, 
rs6032, rs3095447, rs4852954, rs7236163, rs522521, and 
median HbA1c levels. These data suggest that the identi-
fied genetic loci may serve as markers for both, develop-
ment of T2DM complications and alterations in HbA1c 
levels, though the particular analysis should be repeated 
in a different cohort where the variable impact of differ-
ent anti-diabetic medications should also be considered.
By performing targeted analysis of candidate variants 
we managed to replicate three associations with T2DM 
complications in the population of Latvia. Both variants 
(rs3761980 and rs80028505) showing an association with 
T2DM neuropathy are located near the Mitogen-acti-
vated protein kinase 14 coding gene (MAPK14) and have 
been previously linked to increased risk of diabetic foot 
ulcers in the report of The Genetics of Diabetes Audit and 
Research in Tayside Scotland (GoDARTS) project [49]. In 
addition, we found a significant association of rs136161 
located in the Apolipoprotein L1 coding gene (APOL1) 
with T2DM nephropathy, which has been already linked 
to an advanced diabetic kidney disease across multiple 
ethnic groups [50]. Although we have observed smaller 
effect sizes for rs3761980 and rs80028505 comparing to 
other GWAS and much larger effect for rs136161, the 
previously reported odds ratio values for all three vari-
ants fit within the 95% confidence intervals calculated in 
our study [49, 50].
This study has several limitations, though the small 
sample size is the primary limiting factor in the risk 
variant discovery, which may result in an insufficient 
statistical power for the detection of rare variants with 
small effect sizes. This may also explain why variants 
with large effect sizes (OR up to 2.71) are markedly 
represented among the significant results of our study. 
Although the retrospective distribution of cases and 
controls in the analysis of T2DM neuropathy and oph-
thalmic complications was relatively balanced, the lack 
of significant hits in the analysis of diabetic nephropa-
thy may be explained by the high incidence of the spe-
cific type of complication among the study participants 
(86%), leaving the size of the control group too small 
for the identification of true associations. Additionally, 
the suboptimal case-to-control ratio in the analysis of 
macrovascular complications may affect the statisti-
cal power of the study and explain the relatively high 
number of associations identified in the specific com-
plication group. Due to the limited number of study 
subjects, the follow-up period was not fixed or set as 
inclusion criteria, though it was fitted as a covariate in 
the association analysis. Since the duration of diabe-
tes is one of the strongest risk factors for the develop-
ment of vascular complications [51], the use of an equal 
observation period in all cases would reduce the resid-
ual variability and improve the quality of this study.
Successful integration of genotyping data with longi-
tudinal phenotypic information produced from several 
national health registries has provided strong support 
for 10 loci showing a genome-wide significance for the 
association with T2DM complications, some of them 
with already known importance to the comorbid condi-
tions analyzed. We believe that these findings provide 
deeper insight into the pathogenesis of T2DM com-
plications and suggest novel candidate genes for fur-
ther functional studies, while our targeted approach 
highlights several susceptibility loci showing a direc-
tionally consistent impact on phenotype in multiple 
populations.
Conclusions
Using the genome-wide genotyping approach this study 
identified ten novel associations with T2DM compli-
cations, including GYPA (rs1132787) in diabetic neu-
ropathy, PDE4DIP (rs2477088), NAT8 (rs4852954), F5 
(rs6032), RPS6KA2 (rs6935464) in macrovascular com-
plications, and CCDC146 (rs3095447) in ophthalmic 
complications. Meanwhile, the candidate gene analysis 
demonstrated a strong association for diabetic neuropa-
thy (MAPK14: rs3761980, rs80028505), and diabetic 
nephropathy (APOL1: rs136161), proving the contribu-
tion of these risk loci in the pathogenesis of diabetic com-
plications across various populations.
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